Vimseltinib

Vimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R). It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity – the greater selectivity of vimseltinib results in a lower risk of off-target effects, including hepatotoxicity. Vimseltinib – under the brand name Romvimza – was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ROMVIMZA and 2-(isopropylamino)-3-methyl-5-[6-methyl-5-[[2-(1-methylpyrazol-4-yl)-4-pyridyl]oxy]-2-pyridyl]pyrimidin-4-one. Its PubChem CID is 86267612.